Summit Financial Wealth Advisors LLC Purchases 6,201 Shares of Danaher Corporation $DHR

Summit Financial Wealth Advisors LLC acquired a new position in Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 6,201 shares of the conglomerate’s stock, valued at approximately $1,374,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in DHR. BlackRock Inc. purchased a new stake in Danaher during the second quarter valued at about $10,492,520,000. Wellington Management Group LLP increased its stake in shares of Danaher by 10.4% in the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after purchasing an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC purchased a new position in shares of Danaher in the second quarter worth about $1,456,317,000. Generation Investment Management LLP purchased a new position in shares of Danaher in the second quarter worth about $1,287,949,000. Finally, Bank of America Corp DE bought a new stake in shares of Danaher in the second quarter valued at approximately $993,846,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Up 3.0%

DHR stock opened at $231.52 on Friday. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $162.76 billion, a PE ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The stock has a 50-day simple moving average of $213.55 and a two-hundred day simple moving average of $195.74.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same period in the prior year, the business posted $0.77 earnings per share. The company’s revenue was up 5.5% on a year-over-year basis. On average, equities analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s payout ratio is currently 28.42%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on DHR. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. Barclays raised their price objective on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Morgan Stanley lifted their price objective on shares of Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday. Guggenheim lifted their price objective on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Finally, Royal Bank Of Canada boosted their target price on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.